ADVISERS are hoping that the IPO of Burton-based pharmaceutical business Clinigen Group could inspire other companies to seek a listing.

Clinigen will start trading on the Alternative Investment Market (AIM) today with an estimated value of £170m.

The company supplies drugs and technical services to pharmaceutical companies for medical trials, manages drug supplies and sells specialist medication only used in hospitals.

Key to its business model is buying licences for existing drugs and finding......for the full story register now for free or login below...